Kura Oncology, Inc. (KURA) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 14 Buy, 2 Hold.
The consensus price target is $28.20 (low: $15.00, high: $40.00), representing an upside of 208.5% from the current price $9.14.
Analysts estimate Earnings Per Share (EPS) of $-2.45 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.02 vs est $-2.45 (beat +17.6%). 2025: actual $-3.18 vs est $-2.87 (missed -10.8%). Analyst accuracy: 84%.
KURA Stock — 12-Month Price Forecast
$28.20
▲ +208.53% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Kura Oncology, Inc., the average price target is $28.20, with a high forecast of $40.00, and a low forecast of $15.00.
The average price target represents a +208.53% change from the last price of $9.14.
Highest Price Target
$40.00
Average Price Target
$28.20
Lowest Price Target
$15.00
KURA Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Kura Oncology, Inc. in the past 3 months
EPS Estimates — KURA
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.02
vs Est –$2.45
▲ 21.3% off
2025
Actual –$3.18
vs Est –$2.87
▼ 9.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — KURA
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.054B
vs Est $0.050B
▲ 6.8% off
2025
Actual $0.067B
vs Est $0.085B
▼ 26.5% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
